Revolution Medicines

We’re now on Instagram! Follow @revolutionmedicines for culture highlights, milestones, and moments from across our community. https://lnkd.in/gsPHDtcd      #WeAreRevolutionaries 

New roles just launched! Be part of our nationwide Senior Oncology Account Manager team and help bring innovative therapies to patients across the U.S.     Apply today: https://lnkd.in/gpEmmBe6 #RevMed #NowHiring #BeARevolutionary

We’re pleased to announce the U.S. FDA has granted Breakthrough Therapy Designation to our investigational RAS(ON) G12D-selective inhibitor for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer who have been previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy. This recognition marks the first Breakthrough Therapy Designation for a KRAS G12D-mutated NSCLC therapy, underscoring the significant unmet need and the potential of novel targeted approaches for patients living with advanced lung cancer. Learn more: https://lnkd.in/gNzhM3uN

Revolution Medicines CEO and Chairman, Mark A. Goldsmith, M.D., Ph.D., will be delivering a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 10:30 a.m. PT. A live webcast and replay of the presentation will be available on our website under the "Events & Presentations" page. Full details: https://lnkd.in/gWe-6BQs

We're pleased to announce a clinical milestone: the first patient has been randomized in RASolute 304, our global Phase 3 clinical trial evaluating our RAS(ON) multi-selective inhibitor in patients with resectable pancreatic ductal adenocarcinoma (PDAC) following adjuvant chemotherapy. The trial expands the clinical evaluation of our RAS(ON) multi-selective inhibitor into another important treatment setting for patients with RAS mutant pancreatic cancer. Read the full release: https://lnkd.in/gGHYTbkn

Revolution Medicines is proud to pursue recertification with My Green Lab across all our laboratories. Since our initial certification in 2023, we've deepened our commitment to sustainable research, working to minimize the environmental impact of our innovations. This ongoing effort underscores our dedication to embedding sustainability into every aspect of our work and leading by example in the biotech community. Together with My Green Lab, we're advancing a shared vision for a more sustainable future in life sciences, where scientific progress and environmental responsibility go hand in hand. 

Pancreatic ductal adenocarcinoma (PDAC) remains one of the toughest cancers to detect and treat, often diagnosed at an advanced stage when options are limited. During Pancreatic Cancer Awareness Month, we’re joining forces with the community to elevate awareness and accelerate innovation for those facing this disease. More than 90% of PDAC cases are driven by RAS mutations, making RAS not only a major factor in disease progression, but also a promising target for new therapies. Despite its significance, RAS remains under-recognized, and the urgent need for research and effective treatment options has never been greater. At Revolution Medicines, we are dedicated to advancing scientific understanding and developing targeted therapies that may bring new options to patients and their families. Together, with the wider pancreatic cancer community, we’re committed to driving progress in the fight against pancreatic cancer. Learn more about the impact of RAS mutations in pancreatic cancer: https://www.expectras.com/ #ExpectRAS

At this year’s RevIMPACT event, we paused to celebrate progress that will one day potentially benefit patients – from scientific advancements to the everyday acts of teamwork that power our mission.  Thank you to our RevMed team members for your creativity, commitment, and heart.  Here’s to building on our momentum and making an even greater impact in the year ahead! #RevImpact #CompanyCulture #WeAreRevolutionairies #PurposeDriven  

This November, in honor of Lung Cancer Awareness Month, members of the Revolution Medicines team joined the LUNGevity Foundation and fellow volunteers at the National Mall in Washington, D.C. to help plant 60,000 flags, each representing two lives lost to lung cancer. It’s a powerful reminder of why awareness, advocacy, and research matter. Thank you to all who are helping to make a difference.  #LungCancerAwarenessMonth #LCAM #WeAreRevolutionaries

This November, we join GO2 for Lung Cancer and the lung cancer community in recognizing Lung Cancer Awareness Month. It’s a time to honor patients, families, and advocates, researchers and healthcare teams while renewing our commitment towards advancing research and expanding treatment options for those facing this disease. At Revolution Medicines, we remain focused on developing innovative, investigational targeted therapies for RAS-driven lung cancers, bringing renewed hope for those impacted by this challenging diagnosis. Together, we can drive progress, raise awareness, and make a difference for everyone affected by lung cancer. #LungCancerAwarenessMonth #LCAM #AnyoneWithLungs